GBSG — Intelligent Bio Solutions Income Statement
0.000.00%
Last trade - 00:00
HealthcareMicro Cap
- $7.28m
- $6.64m
- $1.26m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.189 | 1.98 | 0.437 | 1.26 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 0.327 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.39 | 3.05 | 7.55 | 8.77 | 13.9 |
Operating Profit | -7.39 | -2.86 | -5.57 | -8.34 | -12.6 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -7.39 | -3.19 | -7.06 | -8.33 | -10.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.39 | -3.19 | -7.06 | -8.33 | -10.7 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -7.34 | -3.16 | -7.04 | -8.31 | -10.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.34 | -3.16 | -7.04 | -8.31 | -10.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -184 | -82.1 | -154 | -136 | -77.3 |
Dividends per Share |